Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Nima Melzer"'
Publikováno v:
Dermatology and Therapy, Vol 9, Iss 3, Pp 579-587 (2019)
Abstract Introduction Plaque psoriasis is a chronic, systemic-inflammatory disease characterized by skin erythema, plaques and scaling, and is associated with different comorbidities like psoriatic arthritis, obesity, and cardiometabolic diseases. Ob
Externí odkaz:
https://doaj.org/article/6f3107b82a244d9aa94faf0e2810c7ce
Autor:
Andreas Pinter, Peter Schwarz, Sascha Gerdes, Jan C. Simon, Anja Saalbach, James Rush, Nima Melzer, Thomas Kramps, Benjamin Häberle, Maximilian Reinhardt
Publikováno v:
Nutrients, Vol 13, Iss 9, p 3015 (2021)
Inflammatory diseases including psoriasis are associated with metabolic and cardiovascular comorbidities, including obesity and metabolic syndrome. Obesity is associated with greater psoriasis disease severity and reduced response to treatment. There
Externí odkaz:
https://doaj.org/article/da6db7c9ac154fdda4bc49ef936dc6a2
Publikováno v:
PharmacoEconomics - open. 6(2)
Objectives Moderate to severe plaque psoriasis is a chronic inflammatory disease. In Germany, guidelines recommend fumaric acid esters (FAEs) as first-line systemic treatment. Despite treatment with FAEs, disease burden remains high in Germany. Secuk
Autor:
Thomas Kramps, Nima Melzer, Anja Saalbach, Andreas Pinter, Benjamin M Häberle, Peter Schwarz, Sascha Gerdes, Maximilian Reinhardt, James S. Rush, Jan C. Simon
Publikováno v:
Nutrients 13:3015 (2021)
Nutrients
Volume 13
Issue 9
Nutrients, Vol 13, Iss 3015, p 3015 (2021)
Nutrients
Volume 13
Issue 9
Nutrients, Vol 13, Iss 3015, p 3015 (2021)
Inflammatory diseases including psoriasis are associated with metabolic and cardiovascular comorbidities, including obesity and metabolic syndrome. Obesity is associated with greater psoriasis disease severity and reduced response to treatment. There
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85f1f7a4b4ccfb2f5c69913cc1601cb2
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=62924
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=62924
Autor:
Diamant Thaçi, E Duetting, Nima Melzer, R von Kiedrowski, Matthias Augustin, T. Kasparek, Andreas Körber, U. Amon, T. Bachhuber, G. Kraehn-Senftleben
Background Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate-to-severe psoriasis. Trial protocols specify transition periods and prohibit concomitant psoriasis medicati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b34b764822179082b951b8a0ec3957bb
https://www.ncbi.nlm.nih.gov/pubmed/31541554
https://www.ncbi.nlm.nih.gov/pubmed/31541554
Autor:
F. Lauffer, Marc Alexander Radtke, Kilian Eyerich, Andreas Pinter, Matthias Augustin, Sascha Gerdes, David M. Pariser, Diamant Thaçi, Nima Melzer, Mark Lebwohl, Kristian Reich, Christian Sieder, Ulrich Mrowietz
Publikováno v:
The British journal of dermatologyReferences. 182(1)
BACKGROUND Conventional analyses present aggregate data, masking late responders and efficacy reductions. Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A, shows sustained efficacy in moderate-to-severe
Autor:
Diamant Thaçi, Kristian Reich, F. Lauffer, Andreas Pinter, Nima Melzer, Mark Lebwohl, Matthias Augustin, Ulrich Mrowietz, Marc Alexander Radtke, Kilian Eyerich, Sascha Gerdes, David M. Pariser, Christian Sieder
Publikováno v:
British Journal of Dermatology. 182:e22-e22
Autor:
Tienush Rassaf, Jennifer Frueh, Kristian Reich, Andreas Pinter, Ari Waisman, Tommaso Gori, Diamant Thaçi, Wolfgang Koenig, Nima Melzer, Andreas Körber, Venkatesh Mani, Esther von Stebut, Denise Yates, Christian Sieder, Nehal N. Mehta
Publikováno v:
The Journal of investigative dermatology. 139(5)
Psoriasis increases the risk of cardiovascular (CV) disease. Secukinumab, a fully human monoclonal antibody against IL-17A, shows significant efficacy in psoriasis, but effects on CV markers are unknown. CARIMA (Evaluation of Cardiovascular Risk Mark
Autor:
Nima Melzer, Diamant Thaçi, Andreas Körber, U. Amon, T. Bachhuber, R von Kiedrowski, Matthias Augustin, G. Kraehn-Senftleben, T. Kasparek
Background Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate to severe psoriasis. However, as per study protocols, transition periods from prior psoriasis treatments of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd63b045be265a13ae049337660ac52a
https://www.ncbi.nlm.nih.gov/pubmed/28960469
https://www.ncbi.nlm.nih.gov/pubmed/28960469